https://www.optimumcomms.com/wp-content/uploads/2023/12/Poolbeg_Logo_300x180px-80x80Web_Logos.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-01-17 08:38:172024-01-17 08:38:17Poolbeg Pharma plc – Further Data Confirms POLB 001’s Potential in Cancer Immunotherapy-Induced Cytokine Release Syndrome (CRS)
https://www.optimumcomms.com/wp-content/uploads/2023/02/AMSilk_Logo_300px-2.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-01-17 08:37:422024-01-17 08:37:42AMSilk and 21st.BIO announce partnership to accelerate the production of advanced materials made from spider silk-based proteins
https://www.optimumcomms.com/wp-content/uploads/2024/01/DISCO_Logo_300x180px-80x80-2.png
758
1104
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-01-16 09:11:312024-01-16 09:13:53DISCO Pharmaceuticals launches as the surfaceome company with EUR 20 Million in Seed Financing
https://www.optimumcomms.com/wp-content/uploads/2023/12/Biocomposites_Logo_300x180px-80x80-1.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-01-16 08:34:192024-01-16 08:35:09Biocomposites expands its international presence by opening new sales and distribution office in Italy
https://www.optimumcomms.com/wp-content/uploads/2024/01/DelSiTech_Logo_300x180px-80x80-1.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-01-16 08:06:072024-01-16 09:14:22DelSiTech Announces Closing of EUR 10 Million Financing Round to Advance its Silica-Based Drug Delivery Technology Platform
https://www.optimumcomms.com/wp-content/uploads/2023/02/FM_Logo_300px.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-01-15 07:15:322024-01-15 07:15:32Futura Medical extends collaboration with Cooper Consumer Health
https://www.optimumcomms.com/wp-content/uploads/2023/02/Ariceum_Logo_300x180px-2.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-01-10 08:44:382024-01-10 08:44:38Ariceum Therapeutics files for UK Clinical Trial Authorisation (CTA) to test its First-in-Class Iodine-123 labelled PARP inhibitor in patients with recurrent glioblastoma
https://www.optimumcomms.com/wp-content/uploads/2023/06/NovoFund_Logo_300x180px-80x80-1.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-01-09 11:48:092024-01-10 16:23:34Novo Nordisk Foundation partners with CARB-X to fight drug-resistant infections
https://www.optimumcomms.com/wp-content/uploads/2023/02/FM_Logo_300px.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-01-09 08:52:542024-01-09 08:52:54Futura Medical plc – Appointment of Roy Davis as Non-Executive Director
https://www.optimumcomms.com/wp-content/uploads/2023/06/Novo_Holdings23_Logo_300x180px-80x80-4.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-01-05 14:00:452024-01-09 11:54:33Revagenix, Inc. Announces Series B Financing to Develop Novel Antibiotics and Additions to its Board of Directors
https://www.optimumcomms.com/wp-content/uploads/2023/06/Novo_Holdings23_Logo_300x180px-80x80-4.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-01-04 08:47:002024-01-04 08:47:002023 Novo Holdings Seed Investments Team Annual Review/Business Update
https://www.optimumcomms.com/wp-content/uploads/2023/12/Biocomposites_Logo_300x180px-80x80-1.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-01-04 08:34:102024-01-04 08:34:10Biocomposites’ investee Renovos Biologics receives FDA Breakthrough Device Designation for its synthetic nanoclay bone fusion gel, RENOVITE® BMP-2
https://www.optimumcomms.com/wp-content/uploads/2023/10/Vicore_Pharma_Logo_300x180px-80x80-1.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-01-04 08:20:572024-01-04 08:34:43Vicore Reports Positive Results for the Pivotal Study of its Digital Therapy for Patients with Pulmonary Fibrosis
https://www.optimumcomms.com/wp-content/uploads/2023/10/splicebio-1.png
1000
1000
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-01-03 08:35:262024-01-03 08:35:26SpliceBio Appoints Leading Ophthalmology Expert Aniz Girach as Chief Medical Officer
https://www.optimumcomms.com/wp-content/uploads/2023/10/Vicore_Pharma_Logo_300x180px-80x80-1.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-01-02 10:00:322024-01-02 10:00:32Vicore Confirms IPF Development Program on Track and Provides Early-Stage Pipeline Updates
https://www.optimumcomms.com/wp-content/uploads/2023/11/IO-Biotech.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2023-12-21 13:41:562023-12-21 13:41:56IO Biotech Announces First Patient Dosed in Phase 2 Neoadjuvant/Adjuvant Solid Tumor Basket Trial
https://www.optimumcomms.com/wp-content/uploads/2023/06/Calliditas_Logo_300x180px-80x80-1.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2023-12-21 09:19:052023-12-21 09:19:05Calliditas Therapeutics announces full FDA approval of TARPEYO®, the only FDA-approved treatment for IgA nephropathy to significantly reduce the loss of kidney function
https://www.optimumcomms.com/wp-content/uploads/2023/02/Neuraxpharm_Logo_300px-1.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2023-12-20 12:41:172023-12-20 12:41:17European Commission revokes all centrally granted generic marketing permissions for dimethyl fumarate (“DMF”), including Dimethyl Fumarate Neuraxpharm
https://www.optimumcomms.com/wp-content/uploads/2023/08/4SC_Logo_300x180px-80x80Web_Logos-1.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2023-12-20 10:04:202023-12-20 10:05:434SC AG – Company Update
https://www.optimumcomms.com/wp-content/uploads/2023/12/Poolbeg_Logo_300x180px-80x80Web_Logos.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2023-12-20 08:36:522023-12-20 08:36:52Poolbeg Pharma plc – Positive Outputs from Lab-Based Analysis of RSV Drug Candidates Identified Using AIFor more information about Optimum Strategic Communications, please get in touch.
